Medtronic‘s Viva cardiac resynchronization therapy-pacemaker (CRT-P) received FDA approval for use on appropriate patients with heart failure or atrioventricular (AV) block. The device made its debut in Europe earlier this year, featuring AdaptivCRT algorithms that constantly monitor the patient and adjust the output signal to help prevent atrial fibrillation.
According to the company, it is “the only algorithm demonstrated to improve heart failure patients’ response to the therapy and reduce the risk of atrial fibrillation, or AF (as compared to conventional biventricular therapy).”
Some of the findings from the AdaptivCRT Trial evaluating the AdaptivCRT algorithm:
- For patients with normal AV conduction, AdaptivCRT showed an increase in CRT response rate of 12 percent at six months;
- Patients with AdaptivCRT demonstrated a 21 percent reduction in heart failure hospitalizations at one year as compared to historical CRT trials;
- Patients with AdaptivCRT demonstrated a 46 percent reduced risk of AF at two years.